Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or pal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res
Hlavní autoři: Rossi, Lorenzo, Biagioni, Chiara, McCartney, Amelia, Migliaccio, Ilenia, Curigliano, Giuseppe, Sanna, Giuseppina, Moretti, Erica, Minisini, Alessandro M., Cinieri, Saverio, Tondini, Carlo, Arpino, Grazia, Bernardo, Antonio, Martignetti, Angelo, Risi, Emanuela, Pestrin, Marta, Boni, Luca, Benelli, Matteo, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Short Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6542028/
https://ncbi.nlm.nih.gov/pubmed/31142370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1149-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky